Open AccessImmuntherapie bei Kopf-Hals-Plattenepithelkarzinomen
Author(s) -
Nikko Brix,
Lara Dunn,
Tanguy Y. Seiwert,
Claus Belka,
Kirsten Lauber
Publication year - 2020
Publication title -
der internist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 19
eISSN - 1432-1289
pISSN - 0020-9554
DOI - 10.1007/s00108-020-00816-x
Subject(s) - medicine , immunotherapy , abscopal effect , oncology , chemotherapy , radiation therapy , head and neck squamous cell carcinoma , epidermal growth factor receptor , head and neck cancer , cancer
The clinical implementation of immunotherapy has broadened the therapeutic options for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Until 2016, the only molecularly targeted therapy was epidermal growth factor receptor (EGFR) blockade. However, immune checkpoint inhibition has recently become part of first-line treatment in recurrent and/or metastatic HNSCC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom